Ibiglustat (hydrochloride)
Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
Product Specifications
CAS Number
1629063-79-1
Product Name Alternative
Venglustat (hydrochloride) ; SAR402671 (hydrochloride) ; GZ402671 (hydrochloride)
UNSPSC
12352005
Target
Glucosylceramide Synthase (GCS)
Type
Reference compound
Related Pathways
Neuronal Signaling
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ibiglustat-hydrochloride.html
Smiles
O=C(O[C@H]1C2CCN(CC2)C1)NC(C)(C3=CSC(C4=CC=C(C=C4)F)=N3)C.Cl
Molecular Formula
C20H25ClFN3O2S
Molecular Weight
425.95
References & Citations
[1]Stojkovska I, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell Tissue Res. 2018;373 (1) :51-60. doi:10.1007/s00441-017-2704-y|[2]Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37 (6) :1013-22.|[3]Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11 (1) :20945. Published 2021 Oct 22. |[4]Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10 (1) :86-98.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC882034-100 1x 100 µL
CD27 (Tumor Necrosis Factor Receptor Superfamily 7) (LPFS2/2034R), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 